Leap Therapeutics reports FY2023 net loss $81.4M; cash $70.6M; DKN-01 data positive

CYPHERPUNK TECHNOLOGIES INC.

Net loss $81.4M in FY2023 vs $54.6M in FY2022; R&D expenses $73.2M.
Cash and equivalents $70.6M at Dec 31, 2023; research incentive receivables $0.8M.
DeFianCe Part A (CRC): 30% ORR, 93% DCR; median PFS 6.3 months in 2L MSS CRC.
Completed enrollment (170 pts) in DisTinGuish Part C for gastric/GEJ cancer; data expected mid-2024.
Randomized Part B of DeFianCe (130 pts) enrolling; 80 enrolled as of Mar 15, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CYPHERPUNK TECHNOLOGIES INC. reported the year ended December 31, 2023 results: net income $81.4 million.

Period: the year ended December 31, 2023
Net income: $81.4 million
Result: reported results

Exact text from the filing

Net Loss was $81.4 million for the year ended December 31, 2023,

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

CYPHERPUNK TECHNOLOGIES INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-035239

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.